Madappa N. Kundranda, “Genomic change index (GCI) and liquid biopsies in predicting and monitoring response to therapy in advanced pancreatic ductal adenocarcinoma (PDAC)”. J Clin Oncol 33, 2015 (suppl 3; abstr 309).
Advanced PDAC is a lethal disease with dismal 5 year survival. The current modalities for monitoring therapy response using serum (CA) 19-9 levels have poor specificity and radiological responses have long lag times. Tests for rapid and accurate clinical assessment are needed for early decision making.
Read the full text on: http://meetinglibrary.asco.org/content/140193-158